Synthetic Triplex Peptide Nucleic Acid-Based Inhibitors for Cancer Therapy
Summary
The USPTO published patent application US20260092085A1 by inventors Bahal, Dhuri, and Slack disclosing novel peptide nucleic acid (PNA) oligomers designed to target microRNA-155 (miR-155) for cancer therapy. The application demonstrates in vivo efficacy in xenograft mouse models showing reduced tumor growth. The PNA oligomers form PNA/RNA/PNA triplex structures when binding target RNA sequences.
What changed
The USPTO published patent application US20260092085A1 for synthetic peptide nucleic acid (PNA) oligomers capable of forming triplex structures with target RNA. The application (No. 18858646, filed April 20, 2023) covers PNA-based anti-microRNA compounds targeting miR-155, which showed significant tumor growth reduction in lymphoma cell lines and xenograft mouse models. The technology enables targeting of both coding and noncoding RNAs for cancer therapy applications.
Patent applications do not impose regulatory compliance obligations on third parties. Inventors and entities in the pharmaceutical/biotechnology sector should consult patent counsel regarding filing strategies, prosecution timelines, and international patent protection options if pursuing similar technologies. This publication has no compliance deadlines or penalties associated with it.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SYNTHETIC TRIPLEX PEPTIDE NUCLEIC ACID-BASED INHIBITORS FOR CANCER THERAPY
Application US20260092085A1 Kind: A1 Apr 02, 2026
Inventors
Raman Bahal, Karishma Dhuri, Frank Slack
Abstract
A novel peptide nucleic acid (PNA) oligomer capable of forming a PNA/RNA/PNA triplex when binding to its target RNA is described. An anti-micro RNA (miRNA) capable of binding miR-155 was designed based on the novel PNA oligomer and was shown to significantly decrease miR-155 expression in vitro in lymphoma cell lines. In vivo testing in xenograft mouse models resulted in reduced miR-155 expression followed by reduced tumor growth. Methods of making and using the novel PNA oligomer for targeting other coding and noncoding RNAs are described.
CPC Classifications
C07K 14/003 A61P 35/00 A61K 38/00
Filing Date
2023-04-20
Application No.
18858646
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.